Team:Evry/Pill design

From 2013.igem.org

(Difference between revisions)
Line 35: Line 35:
</p>
</p>
-
<h2>Barriers to overcome and conditions to fulfill</h2>
+
<h2>Capsule design requirements</h2>
<p>
<p>
-
<b>The challenge here is double</b>. First, we need to <b>overcome the acidity</b> of the stomach which is lethal for most living forms. Secondly, our capsule <b>must dissolve right in the duodenum</b> to deliver the containment at the distal duodenum and the proximal jejunum. Additionnally, we added HPMC (Hydroxypropylmethylcellulose) among the components for the capsule design to optimize bacterial growth. More in detail, right after the split into the duodenum, the obstruction caused by the HPMC in contact of water has been evaluated to have the right viscosity to allow a stagnant growth of the bacteria and also the passage of food.<br>
+
We see three main challenges. First, <b>the capsule must resist the low pH conditions in the stomach</b>, which are lethal to our bacteria. Second, <b>the capsule must rapidly dissolve in the duodenum</b> to deliver its payload to the distal duodenum and the proximal jejunum. Third, <b>the bacteria must have enough time to effectively uptake iron</b>. We thus added HPMC (Hydroxypropylmethylcellulose) to the capsule interior. Once the capsule dissolves, the HPMC expands upon contact with water to slow nutrient movement in the intestine. Pharmaceutical research has evaluated HPMC to have the right viscosity to allow bacterial growth while also permitting the passage of food.<br>
<br>
<br>
</p>
</p>
-
<h2>Design of the capsule, step by step</h2>
+
<h2>Capsule design, step by step</h2>
<br>
<br>
Line 48: Line 48:
<br>
<br>
-
<h3>Which galenic formulation suits the best our purpose?</h3>
+
<h3>Which galenic formulation is best suited for our goals?</h3>
<p>
<p>
-
The first step in the design of our pill is to determine its galenic formulation. We want a <i>per os</i> administration for our bacteria and had the choice between either a tablet or a capsule. A tablet not only requires a heavy and dry compression but also the bacteria in a lyophilized form. This last step consists of extreme variations of temperature and pression which are not favorable for living beings. However, the capsule is more suited for our purpose because it offers the possibility to contain a non-compressed powder and avoids a lyophilization step, thus representing a softer environment for bacteria transport. Additionnaly, lyophilized bacteria have a delayed recovery before starting any metabolic activity in comparison to a dessicated form.
+
The first step in the design of our pill is to determine its galenic formulation. We want a <i>per os</i> administration for our bacteria and had the choice between either a tablet or a capsule. A tablet requires a heavy and dry compression and the bacteria in a lyophilized form, entailling high temperatures and pressures that would result in significant bacterial mortality. We decided a a capsule is more suited for our purpose because it offers the possibility to contain a non-compressed powder and avoids a lyophilization step, thus representing a more favorable environment for bacteria storage. In addition, a capsule avoids lyophilizing the bacteria, which would delay their metabolic activity after being released.
</p>
</p>

Revision as of 04:47, 4 October 2013

Iron coli project

Capsule design

a transport device to deliver our bacteria to the intestine



Bannière gélule

Abstract

Our engineered bacteria need to be delivered to the distal area of the duodenum and the proximal area of the jejunum in order to treat iron adsorption. We thus designed a polymer-based capsule that resists the low pH conditions in the stomach, but will dissolve at intestinal pH. We also improved its galenic formulation to optimize growth.

First, we create a novel capsule following the actual norms from the European Pharmacopeoa concerning gastro-enteric resistant formulations.

Second, we ensure that the bacteria survive following dissolution of the capsule.


Posology

The patient must receive a controlled dose of our engineered bacteria for them to function as as an effective medical treatment. This requires that the capsule be eaten on an empty stomach. In addition, the bacteria must also have enought time to grow once delivered in the duodenum and jejunum. Our strategy focuses on preparing the duodenum of the patient for the next meal and let the bacteria sufficient time to settle and produce sufficient chelators to reduce the iron absorption.

Capsule design requirements

We see three main challenges. First, the capsule must resist the low pH conditions in the stomach, which are lethal to our bacteria. Second, the capsule must rapidly dissolve in the duodenum to deliver its payload to the distal duodenum and the proximal jejunum. Third, the bacteria must have enough time to effectively uptake iron. We thus added HPMC (Hydroxypropylmethylcellulose) to the capsule interior. Once the capsule dissolves, the HPMC expands upon contact with water to slow nutrient movement in the intestine. Pharmaceutical research has evaluated HPMC to have the right viscosity to allow bacterial growth while also permitting the passage of food.

Capsule design, step by step


Capsule

Which galenic formulation is best suited for our goals?

The first step in the design of our pill is to determine its galenic formulation. We want a per os administration for our bacteria and had the choice between either a tablet or a capsule. A tablet requires a heavy and dry compression and the bacteria in a lyophilized form, entailling high temperatures and pressures that would result in significant bacterial mortality. We decided a a capsule is more suited for our purpose because it offers the possibility to contain a non-compressed powder and avoids a lyophilization step, thus representing a more favorable environment for bacteria storage. In addition, a capsule avoids lyophilizing the bacteria, which would delay their metabolic activity after being released.


Capsule

How to store the bacteria in the capsule?

Iron minion
Figure 1: Testing both moisture absorbents.
Iron minion
Figure 2: Hand mortar and pestle, old fashioned but efficient.

The design of a capsule requires every component to be in a powder form. Thus, we tested which one was able to absorb the most LB medium saturated with bacteria. In galenic research, this is called a moisture absorbent and has the right chemical properties to keep our drug (here our bacteria in LB medium) in a dry environment. We experimented and colloidal silica and tried to disperse as much as possible with hand mortar and pestle (figure 1 and 2). Our final choice was colloidal silica for absorbing the most medium.



Iron minion
Figure 3: Preparing the rack with 50 empty capsules.
Iron minion
Figure 4: Filling the capsule with the total amount of powder.

For the next step, we want to increase the volume to 35 mL which is the sufficient amount to make 50 capsules (standard for one rack, figure 3). Thus, a diluent is required and we opted for HPMC (hydroxypropylmethylcellulose). The entire volume of powder has to be equally distributed in the capsules (figure 4).



Iron minion
Figure 5: Closing the capsules after a filling the rack.
Iron minion
Figure 6: Final result, 50 capsules uniformally filled with the powder mixture.

Finally, the 50 capsules contain all together 11 ml of colloidal silica (where 4 mL of saturated bacteria have been dissolved in) and 24 mL of HPMC. The last step is the closing of the capsules (figure 5 and 6).



Capsule

How to overcome the acidity of the stomach?

Dipping
Figure 7: Dipping of the capsule in an alcohol-based methacrylic acid polymere solution.
Hairdryer
Figure 8: Drying of the capsule by evaporating the alcohol.

It is very common in the pharmaceutical world, and more precisely in galenical research, to overcome the acidity of the stomach and to target the duodenum/jejunum for the delivery of the capsule. By a simple saoking of one side of the capsule in an ethanol-based solution of methacrylic acid and followed by a drying process (hot air), we managed to surround our capsule with a double-enveloppe resistant that confers resistance to gastric acidity. The capsule has to resist as long as possible to the gastric content, but not to much otherwise we miss its dissolution in the duodenum.


Capsule

How to deliver the bacteria in the jejunum?

The delivery in the duodenum/jejunum is already possible due to the gelatine-based composition of the capsule. In contact to water, the capsule dissolves and delivers its containment in the duodenum. This is only feasable when the capsule has already resisted to the gastric acidity. Moreover, we added a HPMC as a diulent. In the presence of water, right after the dissolution of the gelatine capsule, it is able to swell. Depending on its density, the polymere forms a more or less viscuous obstruction. This process creates an environment in the jejunum where bacteria can statically proliferate. Thus, HPMC, beside its properties as a diluent, is also called a bio-adhesive for its ability to stick to the membranes of the intestins and form an obstruction.


Capsule

How to prove the real efficiency of our capsule?

As a proof of concept, we fulfilled the two basic requirements of the European Pharmacopeia to make a gastro-enteric resistant capsule which are as follows:

  1. No dissolution of the capsule after 2 hours of exposure to gastric acid (solution at pH = 2)
  2. Dissolution of the capsule within 1 hour of exposure to water (Phosphate Buffer solution, pH = 7) right afterwards

Hairdryer
Figure 9: The dissolution machine.
Hairdryer
Figure 10: The basket that dips into the solution.

The dissolution machine is able to lift a basket up and down into a 800mL beaker (figure 9). For every experience, we were able to test 6 capsules spread into 6 apart columns (figure 10). Keep in mind that these columns have the possibility to be closed by a lid on the top to increase the dissolution and mimic different segments of the intestins.




Capsule integrity 1 hour
Figure 11: Capsule dissolvement stage after 1 hour of exposure to gastric acid.
Turbidity 1 hour
Figure 12: Water turbidity after 1 hour of exposure to gastric acid.

We observe that after one hour of exposure to gastric acidity, the capsules are not dissolved. They kept their integrity (figure 11) and didn't deliver its contanment (figure 12).

Capsule integrity 2 hours
Figure 13: Capsule dissolvement stage after 2 hours of exposure to gastric acid.
Turbidity 2 hours
Figure 14: Water turbidity after 2 hours of exposure to gastric acid.

We observe that after two hours of exposure to gastric acidity, the capsule are still not dissolved. They kept their integrity (figure 13) and didn't deliver its contanment (figure 14).

Final solution color
Figure 15: Final solution color after 2 hours of exposure to gastric acidity.

We observe that the water is very clear (figure 15), thus meaning that the first condition of the European Pharmacopeoa to create a gastro-enteric resistant capsule is fullfilled.




Capsule integrity 0 minute
Figure 16: Capsule dissolvement stage after 0 minute of exposure to PBS buffer (pH = 7,2).
Turbidity integrity 0 minute
Figure 17: Water turbidity after 0 minute of exposure to PBS buffer (pH = 7,2).

We observe that after two hours of exposure to gastric acidity, the capsule are still not dissolved. They kept their integrity (figure 13) and didn't deliver its contanment (figure 14).

Capsule integrity 15 minutes
Figure 18: Capsule dissolvement stage after 15 minutes of exposure to PBS buffer (pH = 7,2).
Turbidity integrity 15 minutes
Figure 19: Water turbidity after 15 minutes of exposure to PBS buffer (pH = 7,2).

We observe that after two hours of exposure to gastric acidity, the capsule are still not dissolved. They kept their integrity (figure 13) and didn't deliver its contanment (figure 14).

Capsule integrity 30 minutes
Figure 20: Capsule dissolvement stage after 30 minutes of exposure to PBS buffer (pH = 7,2).
Turbidity integrity 30 minutes
Figure 21: Water turbidity after 30 minutes of exposure to PBS buffer (pH = 7,2).

We observe that after two hours of exposure to gastric acidity, the capsule are still not dissolved. They kept their integrity (figure 13) and didn't deliver its contanment (figure 14).

Capsule integrity 40 minutes
Figure 22: Capsule dissolvement stage after 40 minutes of exposure to PBS buffer (pH = 7,2).
Turbidity integrity 40 minutes
Figure 23: Water turbidity after 40 minutes of exposure to PBS buffer (pH = 7,2).

We observe that after two hours of exposure to gastric acidity, the capsule are still not dissolved. They kept their integrity (figure 13) and didn't deliver its contanment (figure 14).

Capsule integrity 50 minutes
Figure 16: Capsule dissolvement stage after 50 minutes of exposure to PBS buffer (pH = 7,2).
Turbidity integrity 50 minutes
Figure 17: Water turbidity after 50 minutes of exposure to PBS buffer (pH = 7,2).

We observe that after two hours of exposure to gastric acidity, the capsule are still not dissolved. They kept their integrity (figure 13) and didn't deliver its contanment (figure 14).

Capsule integrity 60 minutes
Figure 16: Capsule dissolvement stage after 60 minutes of exposure to PBS buffer (pH = 7,2).
Turbidity integrity 60 minutes
Figure 17: Water turbidity after 60 minutes of exposure to PBS buffer (pH = 7,2).

We observe that after two hours of exposure to gastric acidity, the capsule are still not dissolved. They kept their integrity (figure 13) and didn't deliver its contanment (figure 14).